

PAPER

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Nanoscale Adv.*, 2024, 6,
3801

Enhanced antibacterial activity of a novel silver-based metal organic framework towards multidrug-resistant *Klebsiella pneumoniae*†

Payam B. Hassan,^a Sameera Sh. Mohammed Ameen,^b Lana Mohammed,^c
Sirwan M. Mohammed Ameen^a and Khalid M. Omer^d  ^{*d}

The growth and spread of multidrug-resistant bacterial species, such as *Klebsiella pneumoniae*, pose a serious threat to human health and require the development of innovative antibacterial agents. The search for an acceptable, safe, and efficient antibacterial is a matter of significant concern. In the present work, silver-based metal-organic frameworks (Ag-MOFs) showed efficient antibacterial activity against multidrug-resistant *K. pneumoniae* (KBP 11) with a minimum inhibitory concentration and minimum bactericidal concentration of 10 $\mu\text{g mL}^{-1}$. Moreover, the Ag-MOF showed enhanced antibacterial activity compared to silver ions and silver nanoparticles. Our experimental investigation showed that the antibacterial efficacy is attributed to the production of reactive oxygen species and the release of cellular constituents, such as K^+ ions and proteins. The MOF scaffold enhances the stability and controlled release of silver ions, enabling sustained antibacterial activity and minimizing the risk of bacterial resistance development. Additionally, the MOF class, due to the high surface area and porous nature, enhances the transfer of bacteria into and on the surface of the MOF.

Received 14th January 2024
Accepted 21st April 2024

DOI: 10.1039/d4na00037d

rsc.li/nanoscale-advances

Introduction

Multidrug resistant bacteria (MDRB) have emerged as a major human health concern, offering a serious challenge to traditional antibiotic therapy.^{1,2} The advent of these resistant strains requires the development of innovative materials for fighting bacterial infections.^{3,4}

K. pneumoniae is a non-motile Gram-negative bacterium, which belongs to the Enterobacteriaceae family, commonly present in the respiratory and gastrointestinal tracts of humans.^{5,6} It causes many infections, including pneumonia, urinary tract infections, septicemia, wound infections, and nosocomial infections within healthcare settings. Significantly, the capacity of this organism to acquire resistance to several antibiotics has resulted in the formation of strains that are resistant to numerous drugs, posing considerable difficulties in medical settings. Due to its clinical impact and potential for antibiotic resistance, effective detection, infection control

strategies, and appropriate antibiotic usage are crucial in managing *K. pneumoniae* infections.^{7,8}

Metal-organic frameworks (MOFs), which consist of crystalline microporous materials made from metal nodes connected by organic linkers, have gained significant interest owing to their wide-ranging properties and potential uses.^{9–14}

MOFs have emerged as interesting possibilities for combating MDRB in recent years due to their unique antibacterial properties.^{15–17} The growing problem of multidrug resistance has encouraged researchers to design and explore alternative strategies beyond conventional antibiotics. MOFs, with their tunable composition, catalytic activity, high surface area, relative biocompatibility, and porous structure, offer a range of distinctive characteristics that can be harnessed to combat bacterial infections, and they can also be used in bioimaging, biosensing for tumor therapy, and as cargo delivery agents for cancer treatment.^{18–22}

Few reports of pure silver-based MOFs with no doping and functionalization have been reported as antimicrobial agents. Lu *et al.*²³ prepared two biocompatible silver carboxylate MOFs, 1 and 2. Both MOFs showed antimicrobial activities towards Gram-negative bacteria, *Escherichia coli* has MIC values of 5–10 and 10–15 ppm. While for a Gram-positive bacterium such as *Staphylococcus aureus*, MIC values were 10–15 and 15–20 ppm. Jaros *et al.*²⁴ prepared a novel bioactive pure Ag-based MOF (bioMOF 1) from silver(I) oxide, 1,3,5-triaza-7-phosphaadamantane (PTA), and pyromellitic acid (H_4pma). The bioMOF 1 showed diverse bioactivity as a robust

^aDepartment of Biology, College of Science, University of Sulaimani, Sulaymaniyah, 46002, Kurdistan Region, Iraq^bDepartment of Chemistry, College of Science, University of Zakho, Zakho, Kurdistan Region, Iraq^cDepartment of Medical Laboratory, College of Health and Medical Technology, Sulaimani Polytechnic University, Sulaymaniyah, Iraq^dDepartment of Chemistry, College of Science, University of Sulaimani, Qlisan St. 46002, Sulaymaniyah, Kurdistan Region, Iraq. E-mail: khalid.omer@univsul.edu.iq† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4na00037d>

antimicrobial agent against pathogenic strains of typical Gram-negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*), Gram-positive bacteria (*Staphylococcus aureus*), and yeast (*Candida albicans*). The minimum inhibitory concentration (MIC) value for Gram-negative bacteria was $5 \mu\text{g mL}^{-1}$.

The principal reason behind the antibacterial activity of pure Ag-MOFs stems from the release of silver ions. The primary objective revolves around liberating these silver ions from the MOF framework, whether through the weakened bond between the ligand and silver metal or the cooperative antibacterial impact with silver. This process facilitates a cascade of reactions involving cell membrane denaturation due to ROS generation or DNA intercalation, hampering cell transcription and replication, and ultimately culminating in bacterial demise.^{16,25,26} Many other articles were reports on using pure Ag-MOF as an antimicrobial agent.^{27–29} However, the majority of the antimicrobial-based Ag-MOFs suffer from the complex structure of the linker and high MIC. In addition, the cytotoxicity of MOFs is of enormous importance. Available toxicity data are rare, most of which are associated with the inorganic and organic precursors rather than the MOFs directly. On comparing MOF cytotoxicity to other commercialized nanosystems, it is lower and strongly associated with its composition.³⁰

Zhang *et al.*¹⁷ developed a $\text{Ag}_2[\text{HBTC}][\text{im}]$ -polylactic acid (PA) fibrous mat, an antibacterial wound dressing, by utilizing silver ion-MOFs, which have the ability to progressively release powerful antibacterial Ag^+ ions to replace antibiotics as the antibacterial agent. The *in vivo* experimental results demonstrated that when used as an antibacterial wound dressing, the wound healing ratio could reach 99.9%, which was significantly higher than that in other comparison groups. This fabricated fibrous mat serves as a valuable guide for the subsequent creation of antibiotic-free wound dressing. In addition, the characterization results showed that the prepared fibrous mat possesses excellent water and thermal stability, up to 300 °C.

He *et al.*³¹ synthesized a novel Ag@MOF@PDA by functionalizing cyclodextrin metal-organic frameworks (CD-MOFs) with polydopamine (PDA) and ultrafine silver nanoparticles (Ag NPs). Under a NIR laser, the constructed Ag@MOF@PDA enhanced the release rate of Ag^+ ions in a controllable way and also efficiently damaged the integrity of biofilms *via* photothermal therapy (PTT). The results demonstrated that the Ag@MOF@PDA nanosystem is effective in healing bacterial and biofilm infections with minimal biotoxicity, and providing a potential antibiotic-free alternative in the “post-antibiotic era.”

In the present work, submicron sized Ag-based MOFs without functionalization and/or encapsulation were prepared from common organic linkers, terephthalic acid, and silver ions. In an effort to broaden the narrow spectrum of antibiotics active against *K. pneumonia*, here, we examined Ag-MOF's *in vitro* susceptibility to clinical isolates of MDR *K. pneumonia*, which are commonly seen in clinical microbiology labs. Moreover, the mechanisms of antibacterial action are also investigated.

Experimental section

Materials and methods

All the information on chemicals and instrumentation are briefly provided in the ESI.†

Synthesis of the Ag-MOF

Briefly, 2 mmol of AgNO_3 , 4 mmol of TP and 8 mmol of TEA were dissolved in 100 mL solution of methanol (50%). Then, the resulting solution was mixed and stirred for 30 minutes and left for 12 hours. The white powder of Ag-MOF was produced and washed with methanol and water many times, respectively. Then, the produced Ag-MOF was dried at 70 °C in a vacuum oven for 24 h.

Bacterial strain used in this study

For the antibacterial experiment, *K. pneumonia* was selected as a model. The multidrug-resistant *K. pneumonia* was isolated from wound swab specimens in Sulaymaniyah Shar Hospital. Molecular identification was applied for further confirmation of the isolate by PCR amplification of 16S rDNA using the primers Lee *et al.*,³² 16S rRNA (sense, 5-TGGCTCAGATTGAACGCTGGCGGC; antisense, 5-TACCTTGTTACGACTTCACCCCA). Using a PCR thermocycler (Techne, USA), the PCR was carried out with 35 cycles at 94 °C for 30 seconds, 62 °C for 40 seconds, and 72 °C for 40 seconds, with a final extension of 5 min at 72 °C and a 4 °C hold. Following the PCR, agarose gel electrophoresis was used to examine the reaction result (1500 bp). Then, the purification of PCR products was applied according to the manufacturer's instructions on the genomic DNA purification kit (Geneaid, Taiwan). DNA sequencing was performed by Macrogen (Seoul, South Korea) using a 3500xL genetic analyzer (Applied Biosystems). Later, sequences were modified manually using the BioEdit software (7.2.5 version). The consensus sequence was BLASTed against the GenBank NCBI's contents after it was submitted to GenBank (National Center for Biotechnology Information, Bethesda, MD, USA) for an entry number. The phylogenetic tree was constructed (Fig. S1, ESI†) by the MEGA 11 program with the neighbor joining method, to represent the phylogenetic position of strain.³³ The antibiotic susceptibility test was carried out for the isolated *K. pneumonia* using automated system VITEK2 with cards AST-N417 for the following antibiotics: piperacillin/tazobactam, cefazolin, cefuroxime, gentamicin, ciprofloxacin, amoxicillin/clavulanic acid, cefuroxime axetil, ceftazidime, ceftriaxone, cefepime, ertapenem, imipenem, meropenem, amikacin, fosfomycin, nitrofurantoin, and trimethoprim/sulfamethoxazole. Additionally, the disc diffusion method according to the Kirby-Bauer method³⁴ was also used for the determination of extra antibiotic sensitivity profiles, using the following antibacterial discs: CFM (cefixime 5 μg), CD (cefdinir 5 μg), CPC (cefpodoxime-clavulanate 40 μg), CPD (cefpodoxime 10 μg), CT (colistin 10 μg), S (streptomycin 10 μg), MXF (moxifloxacin 5 μg), LEV (levofloxacin 5 μg), DO (doxycycline 30 μg), TE (tetracycline 30 μg), TGC (tigecycline 15 μg), FO (fosfomycin 200 μg), AZM (azithromycin 15 μg), and CLR (clarithromycin 15 μg).



Antibacterial activity determination

Evaluation of MIC and MBC. The standard broth micro-dilution method (CLSI 2021) was utilized to determine the minimum inhibitory (MIC) and minimum bactericidal (MBC) concentrations of Ag-MOF. Briefly, the isolate was grown overnight in a nutrient broth medium (NB) at 37 °C with shaking (180 rpm), and then the bacterial inoculum was adjusted to the concentration of 10^6 CFU mL⁻¹. For the MIC test, 100 µL of the bacterial suspension was dispersed in a 96-well plate containing a two-fold dilution of Ag-MOF (40 to 0.15 µg mL⁻¹). Plate wells containing only the medium were used as the negative control, and the wells without Ag-MOF containing only the medium and the bacterial suspension served as the positive control. To detect MIC, the microtiter plates were incubated at 37 °C for 24 h. Then, absorbance of the bacterial culture at 600 nm was measured using a spectrophotometer microplate reader (Biotech µQuant, USA). After MIC determination, the MBC test was performed by spotting aliquots of 5 µL from each well of microtiter plates onto nutrient agar plates, and subsequently, all plates were placed in an incubator set at a temperature of 37 °C for a duration of 24 hours. The MBC value was determined as the minimum concentration at which no observable growth was observed after sub-culturing.^{35–37}

Quantification of reactive oxygen species production. The quantification of reactive oxygen species (ROS) produced by bacterial cells after treatment with Ag-MOF was conducted using the dichlorodihydrofluorescein diacetate (DCFH-DA) method, as described in by Liao *et al.*,³⁸ with a few modifications. The bacterial inoculum, with a concentration of 10^8 colony-forming units per milliliter (CFU mL⁻¹), was exposed to different concentrations of Ag-MOF in order to attain 0.5 MIC and 1 MIC. The suspensions were subjected to incubation at a temperature of 37 °C for 8 hours. The NB medium was used to dilute a 10 mM stock solution of DCFH-DA, which was based on dimethyl sulfoxide, in order to obtain a working solution with a concentration of 1 mM. Following the incubation period, the bacterial suspensions underwent centrifugation at 10 000 g for 10 minutes at 4 °C, and subsequently, the supernatant was discarded. The bacteria were washed and then resuspended in 1.8 mL of PBS buffer. Afterwards, the bacterial suspensions were treated with 200 µL of the prepared solution and incubated at a temperature of 37 °C for 30 minutes in the dark. Then, the cells were subjected to thermal degradation at a temperature of 95 °C for 15 minutes. An ELISA reader was used to detect the absorbance of the resultant lysate at a wavelength of 520 nm. The experiments were performed in triplicate.

Quantification of lipid peroxidation. The quantification of lipid peroxidation was performed using the thiobarbituric acid-reactive substance (TBARS) assay, following the approach described by Tiwari *et al.*,³⁹ with minor modifications. Ag-MOF was used to treat the bacterial culture, which had a concentration of 10^8 CFU mL⁻¹, to final concentrations of 0.5 MIC and 1 MIC in a total volume of 10 mL for each treatment. A control culture was maintained in the absence of Ag-MOF treatment, while the NB medium was used as a negative control. The suspensions were incubated at 37 °C for 8 h, and then the

cultures were centrifuged at 10 000 g for 10 minutes at 4 °C; subsequently, the supernatant was collected. A volume of 500 µL of the supernatant was mixed with 250 µL of a solution containing 20% trichloroacetic acid. The resulting mixture was subjected to centrifugation at 10 000 g for 15 minutes, while maintaining a temperature of 4 °C. Afterwards, a volume of 300 µL of the supernatant was mixed with 200 µL of a TBA buffer solution containing 0.8% TBA in a 2 M NaOH solution. The solution was heated at a temperature of 95 °C for one hour. Subsequently, it was allowed to cool down to ambient temperature. At this point, the absorbance was measured (at a wavelength of 532 nm) using a microtiter ELISA reader. The experiments were conducted in triplicate.

Membrane protein and electrolyte leakage estimation. The integrity of the bacterial cell membrane was investigated after exposure to Ag-MOF by measuring cell membrane leakage proteins and potassium ions. Bacterial cells were grown overnight and their concentration was adjusted to 10^8 CFU mL⁻¹. The culture was then subjected to treatment with Ag-MOF to achieve final concentrations of 0.5 MIC and 1 MIC. Each concentration was prepared with a final volume of 10 mL. The control group consisted of the untreated bacterial culture, while the blank group was composed of the NB medium. The suspensions were incubated for 24 h at 37 °C. Following this, centrifugation was performed at 10 000 g for 30 minutes. The supernatant was used to determine the quantity of proteins that had leaked from the treated cells using the precise technique described in ref. 39. In addition, the determination of potassium ion leakage in the bacterial suspensions was conducted at various time intervals (0, 30, 60, 90, and 120 minutes) following treatment. This was accomplished using the Na-tetraphenylborate (Na-TPB) manual kit, with the measurement being dependent on the turbidity of the suspensions. In summary, a 25 µL supernatant was blended with 1 mL of Na-TPB reagent and subjected to incubation at ambient temperature for 5 minutes. Concurrently, standard potassium was employed as a positive control. Subsequently, the turbidity was quantified through photometric analysis at a wavelength of 578 nm using a spectrophotometer. The experiments were conducted in triplicate.

Results and discussion

Characterization of Ag-MOF

Various characterization techniques were carried out to investigate the morphology, shape and size of the as prepared Ag-MOF. Fig. 1A and B show the FE-SEM images of the Ag-MOFs at two different magnifications. Fig. 1C shows the histogram of particle size diameter of Ag-MOF, with the average particle size between 300 and 600 nm. Elemental analysis using the EDS technique was used to confirm the presence of elements of the Ag-MOF. Fig. 1D shows the presence of Ag, C, and O atoms which confirms the formation of the Ag-MOF. Fig. 1E shows the XRD spectrum of the Ag-MOF. The XPS spectra were obtained to examine the chemical composition of the Ag-MOFs. The survey spectrum (Fig. 1F) shows the peaks of O, C, and Ag. The resolved spectra of Ag in Fig. 1G display two well-resolved peaks of Ag 3d_{3/2} (373.8 eV) and Ag 3d_{5/2} (367.9 eV), respectively.^{40,41} The O 1s






Fig. 1 (A and B) FE-SEM images of the Ag-MOF. (C) Histogram of particle size diameter of Ag-MOF. (D) EDX image of the synthesized Ag-MOF. (E) XRD spectrum of the Ag-MOF. (F) Survey XPS spectrum of the Ag-MOF. Deconvoluted spectra of the elements in the synthesized Ag-MOF. (G) Ag 3d. (H) O 1s. (I) C 1s.

spectra as shown in Fig. 1H have two main peaks at 531.8 and 532.44 eV which are attributed to the O-C=O and C=O bonds in the Ag-MOF.⁴² Fig. 1I shows the C 1s spectrum which reveals three peaks at 288.52, 285.86 and 284.56 eV which are attributed to O-C=O, C=O and C=C.⁴²⁻⁴⁴

Identification of the bacterial strain

The multidrug-resistant *K. pneumonia* was isolated from clinical samples at Shar Hospital in Sulaymaniyah, Iraq. The resulting 16S rRNA sequences for the isolate were compared to the closely comparable sequences present in the NCBI database. The strain exhibited a sequence similarity of 99% to *K. pneumoniae*. The 16S rRNA sequence was submitted to the GenBank (NCBI) with an accession number of OR500977. A phylogenetic tree was created using the 16S rRNA gene sequencing of the isolate. Based on the neighbor joining phylogenetic data, our isolate of *K. pneumonia* KPB11 showed a cluster with *Klebsiella* sp., as seen

in Fig. S1 (ESI†). In addition, the result of antibiotic sensitivity testing by using a VITEK 2 system and the Kirby-Bauer method showed that the strain has resistance to the following antibiotics, including cefepime, ertapenem, piperacillin/tazobactam, cefixime, cefdinir, cefazolin, cefuroxime, amoxicillin/clavulanic acid, cefuroxime axetil, ceftazidime, ceftriaxone, imipenem, meropenem, ciprofloxacin, nitrofurantoin, trimethoprim/sulfamethoxazole, cefpodoxime-clavulanate, cefpodoxime, moxifloxacin, levofloxacin, doxycycline, tetracycline, fosfomycin, azithromycin, and clarithromycin as shown in Table S1 (ESI†).

Antibacterial activity

MOFs are new fascinating microporous biomaterials that found many uses in pharmaceutical and biological applications because they provide an alternative to existing antibacterial agents and have the potential to be an innovative solution to the



issue of microbial drug resistance.³⁰ At different concentrations, the antibacterial activity of the synthesized Ag-MOF was investigated using MIC and MBC evaluations. MBC is the lowest concentration of an antibiotic substance necessary to kill 99.9% of the bacterial population.⁴⁵ MIC is the lowest concentration of an antimicrobial agent that inhibits bacterial growth without killing the bacteria throughout the incubation. The results demonstrated significant dose-dependent antimicrobial activity against the examined bacterium. The MIC and MBC values of Ag-MOF were 10 $\mu\text{g mL}^{-1}$ (Fig. 2A). Furthermore, bacterial proliferation was shown to decrease while the concentration of Ag-MOF increased. According to the findings, Ag-MOF exhibited strong antibacterial action against multidrug-resistant *K. pneumonia* KPB11. Multiple investigations have shown that Ag-MOFs have antibacterial properties against a variety of bacteria, such as *E. coli*, *B. subtilis*, and *S. aureus*.^{23,46} Table 1 displays previous studies examining antibacterial agents and their antibacterial activity, in contrast to our samples. The findings indicate that Ag-MOF has potential for being used as an antibacterial agent in biological applications. The antibacterial

efficacy of Ag-based MOFs is not solely determined by the ligand, but also relies on the liberation of the core metal ion. The Ag-MOF solution releases a greater quantity of Ag^+ ions compared to the Ag-NP solution. Consequently, the antibacterial activity of Ag-based MOFs can be attributed to the release of Ag^+ ions.²³

Antibacterial mechanism

The measurement of proteins and potassium ion leakage from the cell membrane of *K. pneumonia* KPB11 was conducted to investigate the bactericidal mechanism of action of Ag-MOF (Fig. 2). The data presented in Fig. 2B illustrate a substantial increase in protein leakage simultaneously with an increase in the concentration of Ag-MOF. At the outset, a protein leakage of 3.66 $\mu\text{g mL}^{-1}$ was observed in untreated cells. However, cells treated with Ag-MOF at concentrations of 0.5 MIC and 1 MIC showed protein leakages of 79.3 $\mu\text{g mL}^{-1}$ and 108.3 $\mu\text{g mL}^{-1}$, respectively.

Fig. 2C illustrates the amount of potassium ions that were leaked from cells when subjected to varying concentrations of Ag-




Fig. 2 (A) Antibacterial activity of Ag-MOFs against multidrug-resistant *K. pneumonia* KPB11 illustrated the MIC and MBC of nanoparticles in $\mu\text{g mL}^{-1}$ (OD: optical density). Inset: five μL was taken from each well of *K. pneumonia* KPB11 and spotted onto the nutrient agar; (B) cell membrane protein leakage from *K. pneumonia* KPB11; (C) cell membrane potassium ion leakage from *K. pneumonia* KPB11; (D) generation of ROS and lipid peroxidation from *K. pneumonia* KPB11.



Table 1 Comparison of antibacterial activity of different antibacterial agents against bacterial strains

Antibacterial agent	Bacterial strains	MIC ($\mu\text{g mL}^{-1}$)	References
$[(\text{AgL})\text{NO}_3] \cdot 2\text{H}_2\text{O}$	<i>Escherichia coli</i>	300	61
	<i>Staphylococcus aureus</i>	297	
Ag-dop $\gamma\text{-Fe}_2\text{O}_3 @ \text{SiO}_2 @ \text{ZIF-8-Ag}$ (FSZ-Ag)	<i>Escherichia coli</i>	100 000	62
	<i>Staphylococcus aureus</i>	100 000	
Cu(I)MOF-AgCl/Ag	<i>Escherichia coli</i>	7.8	63
	<i>Staphylococcus aureus</i>	16	
Ni-gallate MOF	<i>Pseudomonas aeruginosa</i>	225	64
	<i>Staphylococcus aureus</i>	35	
ZIF-8@ $\text{SnO}_2 @ \text{CoFe}_2\text{O}_4$	<i>Escherichia coli</i>	1250	65
	<i>Staphylococcus aureus</i>	2500	
Ag NPs	<i>Staphylococcus aureus</i>	625	66
Ag NPs	<i>Klebsiella pneumoniae</i>	12.5	67
	<i>Salmonella enteritidis</i>	25	
Na-Alg-s-AgNPs@ SiO_2	<i>Klebsiella pneumoniae</i>	95	68
	<i>Enterobacter cloacae</i>	60	
	<i>Bacillus cereus</i>	80	
Ag-MOF	<i>K. pneumoniae</i> KPB11	10	This study

MOF. The cells exposed to 1 MIC of Ag-MOF exhibited the highest diffusion of potassium ions. The potassium ion leakage levels increased from less than $9.41 \mu\text{g mL}^{-1}$ in the control cells to 38.4, 41.5, 44.7, and $47.8 \mu\text{g mL}^{-1}$ at time intervals of 30, 60, 90, and 120 minutes, respectively. Furthermore, the release of potassium ions from cells that were exposed to a concentration of 0.5 MIC of Ag-MOF was measured at four different time intervals: 30, 60, 90, and 120 minutes. The recorded values for potassium ion leakage were 29.8, 33.9, 38.1, and $38.5 \mu\text{g mL}^{-1}$, respectively.

The exact mechanism underlying the antibacterial activity of Ag-MOF remains unclear, and only a small group of researchers have conducted studies on this topic, although the antibacterial mechanisms of Ag nanoparticles have been extensively investigated for a long time. It is worth noting that the antibacterial activities exhibited by MOFs containing Ag might vary from those observed in commercial Ag nanoparticles. However, several strategies have been proposed to address this issue. The primary mechanism of action may be attributed to the elevated electrical conductivity exhibited by metallic silver.⁴⁷ This results in the generation of static electricity that exhibits a pronounced affinity for sulphur proteins, thereby causing silver ions to adhere to the cellular membrane. The adhesion of silver ions might increase the permeability of the cytoplasmic membrane, ultimately resulting in the disruption of the cell membrane. Furthermore, upon entry into the cells, silver ions induce enzyme inactivation and the generation of ROS.^{48,49} ROS have been found to enhance the occurrence of cell membrane rupture and disrupt processes including DNA replication, transcription and translation.^{50–53}

The current study clearly demonstrates that Ag-MOF exhibits significant capability in disrupting bacterial cell membranes, leading to the release of cellular contents (Fig. 2). This phenomenon has been quantified through the measurement of membrane proteins and the leakage of potassium ions from the cells. Prior research has shown that the bactericidal impact of Ag-MOF on both types of bacteria, Gram-negative *E. coli* and Gram-positive *S. aureus*, is due to the disturbance of cell membrane permeability.²³

To better understand the bactericidal mechanism of Ag-MOF against *K. pneumoniae* KPB11 ROS and lipid peroxidation

production were measured in cells treated with Ag-MOF. The results presented in Fig. 2D demonstrate a significant increase in ROS production in *K. pneumoniae* KPB11. Specifically, untreated cells displayed a ROS production level of $0.07 \mu\text{g mL}^{-1}$, whereas cells treated with a 0.5 MIC of Ag-MOF showed a notably higher ROS production level of $0.23 \mu\text{g mL}^{-1}$. This observed increase represents a more than threefold elevation in ROS production. Simultaneously, the production of ROS increased considerably to $0.47 \mu\text{g mL}^{-1}$ when exposed to a concentration of 1 MIC of Ag-MOF, resulting in a fourfold enhancement. The untreated cells exhibited a lipid peroxidation level of $0.065 \mu\text{g mL}^{-1}$, whereas the cells treated with a 0.5 MIC of MOF-Ag demonstrated an increase to $0.099 \mu\text{g mL}^{-1}$, indicating a 1.5-fold elevation. Nevertheless, the lipid peroxidation levels exhibited a subsequent elevation in cells subjected to a concentration of 1 MIC of MOF-Ag, reaching a value of $0.104 \mu\text{g mL}^{-1}$. This increment corresponds to an approximate 1.6-fold augmentation. Similarly, Mohammed and Hamzah⁵⁴ found that treating pandrug resistant *K. pneumoniae* with AgNPs led to a notable increase in ROS production. Moreover, in a study conducted by Hamida *et al.*,⁵⁵ it was discovered that the exposure of *K. pneumoniae* to AgNPs resulted in a significant increase in the generation of ROS. This increase in ROS levels coincided with a reduction in the functioning of antioxidant enzymes.

The overproduction of ROS within bacterial cells has been documented as a significant mechanism by which Ag nanoparticles induce oxidative stress and subsequent microbial mortality (Fig. 2).^{56,57} Moreover, lipid peroxidation, as evidenced by the presence of malondialdehyde (MDA) as a by-product, is considered a detrimental outcome of increased ROS generation.^{58–60} Based on our findings, it was observed that the production of ROS in *K. pneumoniae* KPB11 exhibited a dose-dependent enhancement. This observation was further shown by the measurement of MDA concentrations, which displayed a similar pattern of escalation. The aforementioned results suggest that the increased production of ROS and subsequent elevation of MDA levels have an indirect impact on the functionality of *K. pneumoniae* KPB11. Fig. 3 shows the schematic diagram of the mechanism of antibacterial action.






Fig. 3 Schematic mechanism of antibacterial activity of Ag-MOF.

Conclusions

Ag-MOFs were fabricated at the nanoscale and utilized as antibacterial agents against MDR *K. pneumoniae* strain KPB11. The results of the study showed that the MIC and MBC values were both $10 \mu\text{g mL}^{-1}$. Furthermore, Ag-MOF may induce the generation of ROS in cells, leading to cell wall damage and the release of cellular biomolecules including K^+ ions and proteins, potentially contributing to its antibacterial effect. The MIC and MBC of the Ag-MOF were lower compared to those of most Ag nanoparticles and Ag^+ ions evaluated against different pathogenic bacteria. This could be due to the greater surface area and porosity of MOFs. Further study is required to determine the antibacterial effectiveness of Ag-MOFs against different pathogenic bacterial strains and to comprehend their precise mechanisms of action.

Conflicts of interest

The authors declare that there are no financial conflicts of interest.

References

- 1 C. M. Courtney, S. M. Goodman, J. A. McDaniel, N. E. Madinger, A. Chatterjee and P. Nagpal, *Nat. Mater.*, 2016, **15**, 529–534.
- 2 A. Parmanik, S. Das, B. Kar, A. Bose, G. R. Dwivedi and M. M. Pandey, *Curr. Microbiol.*, 2022, **79**, 388.
- 3 R. J. Melander and C. Melander, *ACS Infect. Dis.*, 2017, **3**, 559–563.
- 4 M. Khosravi, A. Mirzaie, A. B. Kashtali and H. Noorbazargan, *Arch. Microbiol.*, 2020, **202**, 2105–2115.
- 5 F. Foroohimanjili, A. Mirzaie, S. M. M. Hamdi, H. Noorbazargan, M. Hedayati Ch, A. Dolatabadi, H. Rezaie and F. M. Bishak, *J. Basic Microbiol.*, 2020, **60**, 216–230.
- 6 G. Wang, G. Zhao, X. Chao, L. Xie and H. Wang, *Int. J. Environ. Res. Public Health*, 2020, **17**, 6278.
- 7 T. Le, L. Wang, C. Zeng, L. Fu, Z. Liu and J. Hu, *Antimicrob. Resist. Infect. Control*, 2021, **10**, 41.
- 8 A. Mirzaie and R. Ranjbar, *AMB Express*, 2021, **11**, 122.
- 9 R. Freund, O. Zaremba, G. Arnauts, R. Ameloot, G. Skorupskii, M. Dincă, A. Baykina, J. Gascon, A. Ejsmont, J. Goscińska, M. Kalmutzki, U. Lächelt, E. Ploetz, C. S. Diercks and S. Wuttke, *Angew. Chem., Int. Ed.*, 2021, **60**, 23975–24001.
- 10 Q. Wang and D. Astruc, *Chem. Rev.*, 2020, **120**, 1438–1511.
- 11 S. S. Mohammed Ameen, N. M. Sher Mohammed and K. M. Omer, *Talanta*, 2023, **254**, 124178.
- 12 S. Sh. Mohammed Ameen, N. M. Sher Mohammed and K. M. Omer, *Microchem. J.*, 2022, **181**, 107721.
- 13 A. H. Alshatteri, G. K. Ali and K. M. Omer, *ACS Appl. Mater. Interfaces*, 2023, **15**, 21239–21251.
- 14 S. S. Mohammed Ameen, F. O. Qasim, H. S. Alhasan, K. H. Hama Aziz and K. M. Omer, *ACS Appl. Mater. Interfaces*, 2023, **15**, 46098–46107.
- 15 L. Yan, A. Gopal, S. Kashif, P. Hazelton, M. Lan, W. Zhang and X. Chen, *Chem. Eng. J.*, 2022, **435**, 134975.
- 16 R. Karimi Alavijeh, S. Beheshti, K. Akhbari and A. Morsali, *Polyhedron*, 2018, **156**, 257–278.
- 17 S. Zhang, J. Ye, Y. Sun, J. Kang, J. Liu, Y. Wang, Y. Li, L. Zhang and G. Ning, *Chem. Eng. J.*, 2020, **390**, 124523.
- 18 R. Li, T. Chen and X. Pan, *ACS Nano*, 2021, **15**, 3808–3848.
- 19 K. Chattopadhyay, M. Mandal and D. K. Maiti, *Mater. Adv.*, 2024, **5**, 51–67.



- 20 S. S. Mohammed Ameen and K. M. Omer, *Food Chem.*, 2024, **139**, 139170.
- 21 S. S. M. Ameen, I. B. Qader, H. A. Qader, F. K. Algethami, B. Y. Abdulkhair and K. M. Omer, *Microchim. Acta*, 2023, **191**, 62.
- 22 S. H. Al-Jaf, S. S. Mohammed Ameen and K. M. Omer, *Lab on a Chip*, 2024, **24**, 2306–2316.
- 23 X. Lu, J. Ye, D. Zhang, R. Xie, R. F. Bogale, Y. Sun, L. Zhao, Q. Zhao and G. Ning, *J. Inorg. Biochem.*, 2014, **138**, 114–121.
- 24 S. W. Jaros, J. Król, B. Bażanów, D. Poradowski, A. Chrószcz, D. S. Nesterov, A. M. Kirillov and P. Smoleński, *Molecules*, 2020, **25**, 2119.
- 25 A. Mirzaie, F. Badmasti, H. Dibah, S. Hajrasouliha, F. Yousefi, R. Andalibi, A. B. Kashtali, A. H. Rezaei and R. Bakhtiari, *Iran. J. Public Health*, 2022, **51**, 1097–1106.
- 26 V. Paratore, D. Franco, S. Guglielmino, F. Lo Presti, F. Traina, S. Conoci and G. G. Condorelli, *Mater. Adv.*, 2024, **5**, 1033–1044.
- 27 S. W. Jaros, M. F. C. Guedes da Silva, J. Król, M. Conceição Oliveira, P. Smoleński, A. J. L. Pombeiro and A. M. Kirillov, *Inorg. Chem.*, 2016, **55**, 1486–1496.
- 28 P. Cao, X. Wu, W. Zhang, L. Zhao, W. Sun and Z. Tang, *Ind. Eng. Chem. Res.*, 2020, **59**, 1559–1567.
- 29 B.-P. Xie, J.-W. Chai, C. Fan, J.-H. Ouyang, W.-J. Duan, B. Sun, J. Chen, L.-X. Yuan, X.-Q. Xu and J.-X. Chen, *ACS Appl. Bio Mater.*, 2020, **3**, 8525–8531.
- 30 G. Wyszogrodzka, B. Marszałek, B. Gil and P. Dorożyński, *Drug Discovery Today*, 2016, **21**, 1009–1018.
- 31 Y. He, X. Wang, C. Zhang, J. Sun, J. Xu and D. Li, *Small*, 2023, **19**, 2300199.
- 32 H. W. Lee, Y. M. Koh, J. Kim, J. C. Lee, Y. C. Lee, S. Y. Seol, D. T. Cho and J. Kim, *Clin. Microbiol. Infect.*, 2008, **14**, 49–54.
- 33 K. Tamura, G. Stecher, D. Peterson, A. Filipowski and S. Kumar, *Mol. Biol. Evol.*, 2013, **30**, 2725–2729.
- 34 A. W. Bauer, W. M. Kirby, J. C. Sherris and M. Turck, *Am. J. Clin. Pathol.*, 1966, **45**, 493–496.
- 35 S. Agnihotri, S. Mukherji and S. Mukherji, *RSC Adv.*, 2014, **4**, 3974–3983.
- 36 B. Das, S. K. Dash, D. Mandal, T. Ghosh, S. Chattopadhyay, S. Tripathy, S. Das, S. K. Dey, D. Das and S. Roy, *Arabian J. Chem.*, 2017, **10**, 862–876.
- 37 A. Haddadian, F. F. Robattorki, H. Dibah, A. Soheili, E. Ghanbarzadeh, N. Sartipnia, S. Hajrasouliha, K. Pasban, R. Andalibi, M. H. Ch, A. Azari, A. Chitgarzadeh, A. B. Kashtali, F. Mastali, H. Noorbazargan and A. Mirzaie, *Sci. Rep.*, 2022, **12**, 21938.
- 38 S. Liao, Y. Zhang, X. Pan, F. Zhu, C. Jiang, Q. Liu, Z. Cheng, G. Dai, G. Wu, L. Wang and L. Chen, *Int. J. Nanomed.*, 2019, **14**, 1469–1487.
- 39 V. Tiwari, N. Mishra, K. Gadani, P. S. Solanki, N. A. Shah and M. Tiwari, *Front. Microbiol.*, 2018, **9**, 1218.
- 40 O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, *J. Biol. Chem.*, 1951, **193**, 265–275.
- 41 W. S. A. El-Yazeed and A. I. Ahmed, *RSC Adv.*, 2019, **9**, 18803–18813.
- 42 A. Kushwaha, G. Singh and M. Sharma, *RSC Adv.*, 2020, **10**, 13050–13065.
- 43 G. Kumar and D. T. Masram, *ACS Omega*, 2021, **6**, 9587–9599.
- 44 H. D. Chul, R. Vinodh, C. V. V. Muralee Gopi, C. Deviprasath, H.-J. Kim and M. Yi, *Dalton Trans.*, 2019, **48**, 14808–14819.
- 45 P. Mitra, D. Dutta, S. Das, T. Basu, A. Pramanik and A. Patra, *ACS Omega*, 2018, **3**, 7962–7970.
- 46 M. D. Firouzjaei, A. A. Shamsabadi, M. Sharifian Gh, A. Rahimpour and M. Soroush, *Adv. Mater. Interfaces*, 2018, **5**, 1701365.
- 47 P. R. More, S. Pandit, A. Filippis, G. Franci, I. Mijakovic and M. Galdiero, *Microorganisms*, 2023, **11**, 369.
- 48 T. Ameh, M. Gibb, D. Stevens, S. H. Pradhan, E. Braswell and C. M. Sayes, *Nanomaterials*, 2022, **12**, 2402.
- 49 M. Mehrabi, M. F. Ghasemi, B. Rasti, M. Falahati, A. Mirzaie and A. Hasan, *J. Biomol. Struct. Dyn.*, 2021, **39**, 2595–2606.
- 50 H. M. Abd El Salam, H. N. Nassar, A. S. A. Khidr and T. Zaki, *J. Inorg. Organomet. Polym. Mater.*, 2018, **28**, 2791–2798.
- 51 S. Eckhardt, P. S. Brunetto, J. Gagnon, M. Priebe, B. Giese and K. M. Fromm, *Chem. Rev.*, 2013, **113**, 4708–4754.
- 52 S. W. Jaros, M. F. C. Guedes da Silva, M. Florek, M. C. Oliveira, P. Smoleński, A. J. L. Pombeiro and A. M. Kirillov, *Cryst. Growth Des.*, 2014, **14**, 5408–5417.
- 53 R. Behdad, M. Pargol, A. Mirzaie, S. Z. Karizi, H. Noorbazargan and I. Akbarzadeh, *J. Basic Microbiol.*, 2020, **60**, 494–507.
- 54 L. Mohammed and H. Hamzah, *J. Bionanosci.*, 2024, DOI: [10.1007/s12668-024-01334-y](https://doi.org/10.1007/s12668-024-01334-y).
- 55 R. S. Hamida, M. A. Ali, D. A. Goda, M. I. Khalil and M. I. Al-Zaban, *Front. bioeng. biotechnol.*, 2020, **8**, 433.
- 56 K. Muthukumar, S. Rajakumar, M. N. Sarkar and V. Nachiappan, *Antonie van Leeuwenhoek*, 2011, **99**, 761–771.
- 57 Y. Dong, H. Zhu, Y. Shen, W. Zhang and L. Zhang, *PLoS One*, 2019, **14**, e0222322.
- 58 M. A. Quinteros, V. Cano Aristizábal, P. R. Dalmasso, M. G. Paraje and P. L. Páez, *Toxicol. in Vitro*, 2016, **36**, 216–223.
- 59 Z. Yu, Q. Li, J. Wang, Y. Yu, Y. Wang, Q. Zhou and P. Li, *Nanoscale Res. Lett.*, 2020, **15**, 115.
- 60 M. J. Hajipour, K. M. Fromm, A. Akbar Ashkarran, D. Jimenez de Aberasturi, I. R. d. Larramendi, T. Rojo, V. Serpooshan, W. J. Parak and M. Mahmoudi, *Trends Biotechnol.*, 2012, **30**, 499–511.
- 61 Y. Liu, X. Xu, Q. Xia, G. Yuan, Q. He and Y. Cui, *Chem. Commun.*, 2010, **46**, 2608–2610.
- 62 Z. Rahmati, J. Abdi, M. Vossoughi and I. Alemzadeh, *Environ. Res.*, 2020, **188**, 109555.
- 63 F. Mao, Y. Su, X. Sun, B. Li and P. F. Liu, *ACS Omega*, 2023, **8**, 2733–2739.
- 64 A. A. G. El-Shahawy, E. M. Dief, S. I. El-Dek, A. A. Farghali and F. I. Abo El-Ela, *Cancer Nanotechnol.*, 2023, **14**, 60.
- 65 R. Roudbari, N. Keramati and M. Ghorbani, *J. Mol. Liq.*, 2021, **322**, 114524.
- 66 P. Parvekar, J. Palaskar, S. Metgud, R. Maria and S. Dutta, *Biomater. Invest. Dent.*, 2020, **7**, 105–109.
- 67 M. A. Huq and S. Akter, *Molecules*, 2021, **26**, 5996.
- 68 S. Pandey and J. Ramontja, *Int. J. Biol. Macromol.*, 2016, **93**, 712–723.

